Exact Mass: 624.3199204

Dauricine

C38H44N2O6 (624.3199204)

Dauricine is a bisbenzylisoquinoline alkaloid resulting from the formal oxidative dimerisation of 4-{[(1R)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}phenol by attachment of the phenolic oxygen of one molecule to the benzene ring of the second (ortho to the phenolic hydroxy group of the latter). It has a role as a plant metabolite. It is a tertiary amino compound, a member of phenols, an aromatic ether, a member of isoquinolines and a bisbenzylisoquinoline alkaloid. Dauricine is a natural product found in Nelumbo nucifera, Menispermum canadense, and Menispermum dauricum with data available. A bisbenzylisoquinoline alkaloid resulting from the formal oxidative dimerisation of 4-{[(1R)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}phenol by attachment of the phenolic oxygen of one molecule to the benzene ring of the second (ortho to the phenolic hydroxy group of the latter). D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents Dauricine, a bisbenzylisoquinoline alkaloid in Menispermum dauricum, possesses anti-inflammatory activity. Dauricine inhibits cell proliferation and invasion, and induces apoptosis by suppressing NF-κB activation in a dose- and time-dependent manner in colon cancer[1]. Dauricine, a bisbenzylisoquinoline alkaloid in Menispermum dauricum, possesses anti-inflammatory activity. Dauricine inhibits cell proliferation and invasion, and induces apoptosis by suppressing NF-κB activation in a dose- and time-dependent manner in colon cancer[1].

Caribenolide I

C33H52O11 (624.3509442)

Neferine

C38H44N2O6 (624.3199204)

Neferine is found in coffee and coffee products. Neferine is an alkaloid from the seed embryo of Nelumbo nucifera (East Indian lotus Alkaloid from the seed embryo of Nelumbo nucifera (East Indian lotus). Neferine is found in coffee and coffee products. Neferine is a major bisbenzylisoquinline alkaloid. Neferine strongly inhibits NF-κB activation. Neferine is a major bisbenzylisoquinline alkaloid. Neferine strongly inhibits NF-κB activation.

Cyclo(D-Trp-D-Asp-Pro-D-Ile-Leu)

C32H44N6O7 (624.3271314000001)

Dauricine

C38H44N2O6 (624.3199204)

N-[2-(Dimethylamino)ethyl]-N-methyl-4-[({4-[4-morpholin-4-yl-7-(2,2,2-trifluoroethyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]phenyl}carbamoyl)amino]benzamide

C31H35F3N8O3 (624.2784076)

PA(8:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C33H53O9P (624.3427018)

PA(8:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 4-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/8:0)

C33H53O9P (624.3427018)

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/8:0), in particular, consists of one chain of one 4-hydroxy-docosahexaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C33H53O9P (624.3427018)

PA(8:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 7-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/8:0)

C33H53O9P (624.3427018)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/8:0), in particular, consists of one chain of one 7-hydroxy-docosahexaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C33H53O9P (624.3427018)

PA(8:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 14-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/8:0)

C33H53O9P (624.3427018)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/8:0), in particular, consists of one chain of one 14-hydroxy-docosahexaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C33H53O9P (624.3427018)

PA(8:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 17-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/8:0)

C33H53O9P (624.3427018)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/8:0), in particular, consists of one chain of one 17-hydroxy-docosahexaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C33H53O9P (624.3427018)

PA(8:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 16,17-epoxy-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/8:0)

C33H53O9P (624.3427018)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/8:0), in particular, consists of one chain of one 16,17-epoxy-docosapentaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

Neferin

C38H44N2O6 (624.3199204)

Neferine is a member of isoquinolines. Neferine is a natural product found in Nelumbo nucifera with data available. Neferine is a major bisbenzylisoquinline alkaloid. Neferine strongly inhibits NF-κB activation. Neferine is a major bisbenzylisoquinline alkaloid. Neferine strongly inhibits NF-κB activation.

Khelmarin C

C38H40O8 (624.2723040000001)

Scortechinone I

C35H44O10 (624.2934324)

Ligurobustoside B

C31H44O13 (624.2781774)

Bisnorponcitrin

C38H40O8 (624.2723040000001)

5-Acetoxy-11,13-epoxy-2,4-dihydroxykleinifulgin

C32H48O12 (624.3145608)

Taxuspine M

C35H44O10 (624.2934324)

Thalisopidine

C37H40N2O7 (624.283537)

Simplexin E

C33H52O11 (624.3509442)

ligurobustoside I

C31H44O13 (624.2781774)

Fenfangjine B

C37H40N2O7 (624.283537)

(-)-Limacine, 2-beta-N-oxide

C37H40N2O7 (624.283537)

Limacusine 2-beta-N-oxide

C37H40N2O7 (624.283537)

Ligurobustoside F

C31H44O13 (624.2781774)

Gaudichaudiic acid G

C38H40O8 (624.2723040000001)

An organic heteroheptacyclic compound isolated from the bark of Indonesian Garcinia gaudichaudii and exhibits cytotoxic activity.

(-)-Limacine 2-alpha-N-oxide

C37H40N2O7 (624.283537)

Methyl glucosyl-3,4-dehydro-apo-8-lycopenate

C37H52O8 (624.3661992)

24-epipetunioside C

C33H52O11 (624.3509442)

Neothalibrine

C38H44N2O6 (624.3199204)

ichangensin 17-beta-D-glucopyranoside

C31H44O13 (624.2781774)

(-)-northalfoetidine

C37H40N2O7 (624.283537)

1,2-O-benzylidene-9-oxo-10-acetyl-5-cinnamoyltaxicine I

C38H40O8 (624.2723040000001)

podecdysone B 25-O-beta-D-glucopyranoside

C33H52O11 (624.3509442)

C35H44O10

C35H44O10 (624.2934324)

26-O-beta-D-glucopyranosyl-22alpha-furosta-5,25(27)-diene-1beta,3beta,11alpha,22alpha,26-pentaol|26-[(beta-D-glucopyranosyl)oxy]-22alpha-hydroxyfurosta-5,25(27)-diene-1beta,3beta,11alpha-triol|helleboroside B

C33H52O11 (624.3509442)

(+)-chenabine

C37H40N2O7 (624.283537)

(25R)-spirost-7-ene-2alpha,3beta,5alpha,9alpha-tetrol 3-O-beta-D-glucopyranoside

C33H52O11 (624.3509442)

N-Desmethylthalidezine

C37H40N2O7 (624.283537)

9??-Acetyl-10??-deacetyl-spicatine

C35H44O10 (624.2934324)

Pisopowiarine

C38H44N2O6 (624.3199204)

6-acetylswietenine

C35H44O10 (624.2934324)

3-deacetoxyviolide T

C32H48O12 (624.3145608)

phlomisoside IV

C32H48O12 (624.3145608)

Ecdysterone 2,3-acetonide 22-O-benzoate

C37H52O8 (624.3661992)

Acobretine D

C35H48N2O8 (624.3410488)

Ohchinolid B|Ohchinolide B

C35H44O10 (624.2934324)

3-O-stearyl-3,4,5,7-tetra-O-methylquercetin

C37H52O8 (624.3661992)

14-deoxy-14alpha,15alpha-epoxyponasteroside A|brainesteroside A

C33H52O11 (624.3509442)

solanolactoside B

C33H52O11 (624.3509442)

THALIBRINE

C38H44N2O6 (624.3199204)

ptychantin G

C32H48O12 (624.3145608)

Pisopowetine

C38H44N2O6 (624.3199204)

guianensine

C39H36N4O4 (624.2736416)

Anthogorgiene K

C44H48O3 (624.3603257999999)

mesendanin A

C35H44O10 (624.2934324)

mandelalide A

C33H52O11 (624.3509442)

(1S,4S,5S,6R,7R,8S,9R,10S)1,6-diacetoxy-9-benzoyloxy-4,8,15-trihydroxy-dihydro-beta-agarofuran

C35H44O10 (624.2934324)

(5alpha)-pregna-16-en-3beta-ol-20-one 6-O-[alpha-L-rhamnopyranosyl-(1?3)-beta-D-quinovopyranoside]|torvpregnanoside A

C33H52O11 (624.3509442)

7-Deepoxy,6-hydroxy,7-chloro,2,3,4,5-tetrahydro-Huratoxin

C34H53ClO8 (624.3428768)

rhodostreptomycin B

C22H40N8O13 (624.271471)

(-)-northalrugosidine|N2-De-Me-Thalrugosidine

C37H40N2O7 (624.283537)

3-(3,4-Dihydroxybenzoyl)-2,3,27-Thrihydroxy-12-lupen-28-oic acid

C37H52O8 (624.3661992)

6,6,7-trimethoxy-2,2-dimethyl-thalidasane-7,12-diol|O7-demethyl-thalfetidine|O7-demethyl-thalfoetidine|Thaligosidine

C37H40N2O7 (624.283537)

C31H44O13

C31H44O13 (624.2781774)

scupontin C

C32H48O12 (624.3145608)

6-acetyl-3-tigloylswietenolide

C35H44O10 (624.2934324)

2-hydroxythymol 3-O-(4-O-isovaleryl-beta-D-fucopyranosyl)-(1->3)-(4-O-angeloyl)-beta-D-quinovopyranoside

C32H48O12 (624.3145608)

(25S)-22alpha,25-epoxy-3beta,11alpha-dihydroxyfurost-5-en-26-yl beta-D-glucopyranoside

C33H52O11 (624.3509442)

Ohchinolid B

C35H44O10 (624.2934324)

3,4a,5,7,6,8-Hexamethoxy-4,6,7-triisopropyl-3,4a,4,9a-tetrahydrospiro[9H-xanthene-1(2H),2-[2H]-1-benzopyran]-2-one

C36H48O9 (624.3298158)

2-hydroxythymol 3-O-(4-O-(2-methylbutyryl)-beta-D-fucopyranosyl)-(1->3)-(4-O-angeloyl)-beta-D-quinovopyranoside

C32H48O12 (624.3145608)

Lys Leu His Val Asp

C28H48N8O8 (624.3594928)

Leu Asp Val Lys His

C28H48N8O8 (624.3594928)

Leu Thr Ser Lys Tyr

C29H48N6O9 (624.3482597999999)

Glu Gly Lys Tyr Glu

C27H40N6O11 (624.275493)

Glu Lys Trp Tyr

C31H40N6O8 (624.290748)

Glu Lys Tyr Trp

C31H40N6O8 (624.290748)

Glu Trp Lys Tyr

C31H40N6O8 (624.290748)

Glu Trp Tyr Lys

C31H40N6O8 (624.290748)

Glu Tyr Lys Trp

C31H40N6O8 (624.290748)

Glu Tyr Trp Lys

C31H40N6O8 (624.290748)

Phe Phe Arg Arg

C30H44N10O5 (624.3495974)

Phe Arg Phe Arg

C30H44N10O5 (624.3495974)

Phe Arg Arg Phe

C30H44N10O5 (624.3495974)

His Pro Trp Trp

C33H36N8O5 (624.2808526)

His Trp Pro Trp

C33H36N8O5 (624.2808526)

His Trp Trp Pro

C33H36N8O5 (624.2808526)

Lys Glu Trp Tyr

C31H40N6O8 (624.290748)

Lys Glu Tyr Trp

C31H40N6O8 (624.290748)

Lys Trp Glu Tyr

C31H40N6O8 (624.290748)

Lys Trp Tyr Glu

C31H40N6O8 (624.290748)

Lys Tyr Glu Trp

C31H40N6O8 (624.290748)

Lys Tyr Trp Glu

C31H40N6O8 (624.290748)

Met Arg Arg Tyr

C26H44N10O6S (624.3165844)

Met Arg Tyr Arg

C26H44N10O6S (624.3165844)

Met Tyr Arg Arg

C26H44N10O6S (624.3165844)

Pro His Trp Trp

C33H36N8O5 (624.2808526)

Pro Trp His Trp

C33H36N8O5 (624.2808526)

Pro Trp Trp His

C33H36N8O5 (624.2808526)

Arg Phe Phe Arg

C30H44N10O5 (624.3495974)

Arg Phe Arg Phe

C30H44N10O5 (624.3495974)

Arg Met Arg Tyr

C26H44N10O6S (624.3165844)

Arg Met Tyr Arg

C26H44N10O6S (624.3165844)

Arg Arg Phe Phe

C30H44N10O5 (624.3495974)

Arg Arg Met Tyr

C26H44N10O6S (624.3165844)

Arg Arg Tyr Met

C26H44N10O6S (624.3165844)

Arg Thr Trp Tyr

C30H40N8O7 (624.3019810000001)

Arg Thr Tyr Trp

C30H40N8O7 (624.3019810000001)

Arg Trp Thr Tyr

C30H40N8O7 (624.3019810000001)

Arg Trp Tyr Thr

C30H40N8O7 (624.3019810000001)

Arg Tyr Met Arg

C26H44N10O6S (624.3165844)

Arg Tyr Arg Met

C26H44N10O6S (624.3165844)

Arg Tyr Thr Trp

C30H40N8O7 (624.3019810000001)

Arg Tyr Trp Thr

C30H40N8O7 (624.3019810000001)

Thr Arg Trp Tyr

C30H40N8O7 (624.3019810000001)

Thr Arg Tyr Trp

C30H40N8O7 (624.3019810000001)

Thr Trp Arg Tyr

C30H40N8O7 (624.3019810000001)

Thr Trp Tyr Arg

C30H40N8O7 (624.3019810000001)

Thr Tyr Arg Trp

C30H40N8O7 (624.3019810000001)

Thr Tyr Trp Arg

C30H40N8O7 (624.3019810000001)

Trp Glu Lys Tyr

C31H40N6O8 (624.290748)

Trp Glu Tyr Lys

C31H40N6O8 (624.290748)

Trp His Pro Trp

C33H36N8O5 (624.2808526)

Trp His Trp Pro

C33H36N8O5 (624.2808526)

Trp Lys Glu Tyr

C31H40N6O8 (624.290748)

Trp Lys Tyr Glu

C31H40N6O8 (624.290748)

Trp Pro His Trp

C33H36N8O5 (624.2808526)

Trp Pro Trp His

C33H36N8O5 (624.2808526)

Trp Arg Thr Tyr

C30H40N8O7 (624.3019810000001)

Trp Arg Tyr Thr

C30H40N8O7 (624.3019810000001)

Trp Thr Arg Tyr

C30H40N8O7 (624.3019810000001)

Trp Thr Tyr Arg

C30H40N8O7 (624.3019810000001)

Trp Trp His Pro

C33H36N8O5 (624.2808526)

Trp Trp Pro His

C33H36N8O5 (624.2808526)

Trp Tyr Glu Lys

C31H40N6O8 (624.290748)

Trp Tyr Lys Glu

C31H40N6O8 (624.290748)

Trp Tyr Arg Thr

C30H40N8O7 (624.3019810000001)

Trp Tyr Thr Arg

C30H40N8O7 (624.3019810000001)

Tyr Glu Lys Trp

C31H40N6O8 (624.290748)

Tyr Glu Trp Lys

C31H40N6O8 (624.290748)

Tyr Lys Glu Trp

C31H40N6O8 (624.290748)

Tyr Lys Trp Glu

C31H40N6O8 (624.290748)

Tyr Met Arg Arg

C26H44N10O6S (624.3165844)

Tyr Arg Met Arg

C26H44N10O6S (624.3165844)

Tyr Arg Arg Met

C26H44N10O6S (624.3165844)

Tyr Arg Thr Trp

C30H40N8O7 (624.3019810000001)

Tyr Arg Trp Thr

C30H40N8O7 (624.3019810000001)

Tyr Thr Arg Trp

C30H40N8O7 (624.3019810000001)

Tyr Thr Trp Arg

C30H40N8O7 (624.3019810000001)

Tyr Trp Glu Lys

C31H40N6O8 (624.290748)

Tyr Trp Lys Glu

C31H40N6O8 (624.290748)

Tyr Trp Arg Thr

C30H40N8O7 (624.3019810000001)

Tyr Trp Thr Arg

C30H40N8O7 (624.3019810000001)

LSFMQ

C28H44N6O8S (624.2941184)

EGKYE

C27H40N6O11 (624.275493)

CAY10626

C31H35F3N8O3 (624.2784076)

PI(20:2(11Z,14Z)/0:0)

C29H53O12P (624.3274468)

LPI 20:2

C29H53O12P (624.3274468)

PHOHA-PG

C29H53O12P (624.3274468)

OG-PG

C29H53O12P (624.3274468)

Brainesteroside A

C33H52O11 (624.3509442)

Spongipregnoloside A

C33H52O11 (624.3509442)

ST 33:2_O7

C33H52O11 (624.3509442)

Aspacoside A

C33H52O11 (624.3509442)

Aspacoside B

C33H52O11 (624.3509442)

1-(D-Mannosyloxy)-3,4-didenhydro-1,2-dihydro-8-apolycopen-8-oic acid

C37H52O8 (624.3661992)

Methyl mannosyl-3,4-dehydro-apo-8-lycopenoate

C37H52O8 (624.3661992)

Methyl glucosyl-3,4-dehydro-apo-8-lycopenoate

C37H52O8 (624.3661992)

JKC-301

C32H44N6O7 (624.3271314000001)

1,1-DIHEXYL-3,3,3,3-TETRAMETHYLINDOCARBOCYANINE IODIDE

C35H49IN2 (624.2940304000001)

1,3,3-trimethyl-2-(2-(2-phenyl-3-[2-(1,3,3-trimethyl-2,3-dihydro-1h-2-indolyliden)ethylidene]-1-cyclohexenyl)-1-ethenyl)-3h-indolium perchloride

C38H41ClN2O4 (624.2754696000001)

HCV-IN-30

C36H44N6O4 (624.3423864)

Fmoc-D-Lys(Mtt)-OH

C41H40N2O4 (624.298792)

2-(3-methoxy-2-propoxy-5-((2S,5S)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl)phenylsulfonyl)ethanol

C31H48O9SSi (624.2788158000001)

PL-100 PL100

C33H44N4O6S (624.2981404)

1-[2,2-Difluoro-2-(3,4,5-trimethoxy-phenyl)-acetyl]-piperidine-2-carboxylic acid 4-phenyl-1-(3-pyridin-3-YL-propyl)-butyl ester

C35H42F2N2O6 (624.3010776000001)

3-[(21S,22S)-26-ethyl-4-hydroxy-16-(1-hydroxyethyl)-12-(hydroxymethyl)-17,19,21-trimethyl-11-(2-methylpropyl)-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,3,5,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid

C37H44N4O5 (624.3311534)

N-[2-(Dimethylamino)ethyl]-N-methyl-4-[({4-[4-morpholin-4-yl-7-(2,2,2-trifluoroethyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]phenyl}carbamoyl)amino]benzamide

C31H35F3N8O3 (624.2784076)

PA(8:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C33H53O9P (624.3427018)

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/8:0)

C33H53O9P (624.3427018)

PA(8:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C33H53O9P (624.3427018)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/8:0)

C33H53O9P (624.3427018)

PA(8:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C33H53O9P (624.3427018)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/8:0)

C33H53O9P (624.3427018)

PA(8:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C33H53O9P (624.3427018)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/8:0)

C33H53O9P (624.3427018)

PA(8:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C33H53O9P (624.3427018)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/8:0)

C33H53O9P (624.3427018)

1-(1,3-benzodioxol-5-yl)-3-[(3S,9R,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C34H48N4O7 (624.3522817999999)

1-(1,3-benzodioxol-5-yl)-3-[(3R,9R,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C34H48N4O7 (624.3522817999999)

1-(1,3-benzodioxol-5-yl)-3-[(3R,9R,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C34H48N4O7 (624.3522817999999)

1-(1,3-benzodioxol-5-yl)-3-[(3R,9R,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C34H48N4O7 (624.3522817999999)

1-(1,3-benzodioxol-5-yl)-3-[(3S,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C34H48N4O7 (624.3522817999999)

(3R)-2-[(R)-tert-butylsulfinyl]-4-[3-[3-[dimethylamino(oxo)methyl]phenyl]phenyl]-3-(2-hydroxyethyl)-N-(phenylmethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide

C36H40N4O4S (624.277012)

(3S)-2-[(S)-tert-butylsulfinyl]-4-[3-[4-[dimethylamino(oxo)methyl]phenyl]phenyl]-3-(2-hydroxyethyl)-N-(phenylmethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide

C36H40N4O4S (624.277012)

1-(1,3-benzodioxol-5-yl)-3-[(3R,9S,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C34H48N4O7 (624.3522817999999)

1-(1,3-benzodioxol-5-yl)-3-[(3S,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C34H48N4O7 (624.3522817999999)

1-(1,3-benzodioxol-5-yl)-3-[(3R,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C34H48N4O7 (624.3522817999999)

(3S)-2-[(S)-tert-butylsulfinyl]-4-[3-[3-[dimethylamino(oxo)methyl]phenyl]phenyl]-3-(2-hydroxyethyl)-N-(phenylmethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide

C36H40N4O4S (624.277012)

(3R)-2-[(R)-tert-butylsulfinyl]-4-[3-[4-[dimethylamino(oxo)methyl]phenyl]phenyl]-3-(2-hydroxyethyl)-N-(phenylmethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide

C36H40N4O4S (624.277012)

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (11Z,14Z)-icosa-11,14-dienoate

C29H53O12P (624.3274468)

Smgdg O-17:2_3:0

C29H52O12S (624.3179312)

Smgdg O-18:2_2:0

C29H52O12S (624.3179312)

Smgdg O-16:2_4:0

C29H52O12S (624.3179312)

[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

C28H49O13P (624.2910634)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C28H49O13P (624.2910634)

[1-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C32H49O10P (624.3063184)

2-[[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C33H55NO8P+ (624.36651)

1-(9Z-octadecenoyl)-2-glutaryl-sn-glycero-3-phospho-(1-sn-glycerol)

C29H53O12P (624.3274468)

Spongipregnoloside B

C33H52O11 (624.3509442)

1-(11Z,14Z-eicosadienoyl)-glycero-3-phospho-(1-myo-inositol)

C29H53O12P (624.3274468)

SMGDG O-20:2

C29H52O12S (624.3179312)

SQDG 20:1

C29H52O12S (624.3179312)

DGMG 14:1

C29H52O14 (624.3356891999999)

SQMG 21:1

C30H56O11S (624.3543146000001)

DGGA 23:5;O

C32H48O12 (624.3145608)

DGGA 24:4

C33H52O11 (624.3509442)

PA 18:3/12:3;O

C33H53O9P (624.3427018)

PA 20:3/9:4;O2

C32H49O10P (624.3063184)

PA 20:5/8:3;O3

C31H45O11P (624.2699349999999)

PA 22:4/7:3;O2

C32H49O10P (624.3063184)

PA 22:5/7:2;O2

C32H49O10P (624.3063184)

PA 22:5/8:1;O

C33H53O9P (624.3427018)

PA 28:8;O3

C31H45O11P (624.2699349999999)

PA 29:7;O2

C32H49O10P (624.3063184)

PA 30:6;O

C33H53O9P (624.3427018)

PG O-16:0/7:3;O3

C29H53O12P (624.3274468)

PG O-16:0/8:2;O2

C30H57O11P (624.3638301999999)

PG O-23:3;O3

C29H53O12P (624.3274468)

PG O-24:2;O2

C30H57O11P (624.3638301999999)

PG P-16:0/7:2;O3

C29H53O12P (624.3274468)

PG P-16:0/8:1;O2

C30H57O11P (624.3638301999999)

PG P-20:0/4:1;O2

C30H57O11P (624.3638301999999)

PG 14:0/8:3;O3

C28H49O13P (624.2910634)

PG 14:1/8:2;O3

C28H49O13P (624.2910634)

PG 14:1/9:1;O2

C29H53O12P (624.3274468)

PG 16:0/7:2;O2

C29H53O12P (624.3274468)

PG 16:0/8:1;O

C30H57O11P (624.3638301999999)

PG 18:1/5:1;O2

C29H53O12P (624.3274468)

PG 20:0/4:1;O

C30H57O11P (624.3638301999999)

PG 22:3;O3

C28H49O13P (624.2910634)

PG 24:1;O

C30H57O11P (624.3638301999999)

PG 22:6/4:1

C32H49O10P (624.3063184)

PG 26:7

C32H49O10P (624.3063184)

PI O-16:1/4:1

C29H53O12P (624.3274468)

PI O-16:2/4:0

C29H53O12P (624.3274468)

PI O-18:2/2:0

C29H53O12P (624.3274468)

PI O-20:2

C29H53O12P (624.3274468)

PI P-16:0/4:1

C29H53O12P (624.3274468)

PI P-16:0/4:1 or PI O-16:1/4:1

C29H53O12P (624.3274468)

PI P-16:1/4:0

C29H53O12P (624.3274468)

PI P-16:1/4:0 or PI O-16:2/4:0

C29H53O12P (624.3274468)

PI P-18:1/2:0

C29H53O12P (624.3274468)

PI P-18:1/2:0 or PI O-18:2/2:0

C29H53O12P (624.3274468)

PI P-20:1

C29H53O12P (624.3274468)

PI P-20:1 or PI O-20:2

C29H53O12P (624.3274468)

PI 15:1/4:1

C28H49O13P (624.2910634)

PI 17:2/2:0

C28H49O13P (624.2910634)

PI 19:2

C28H49O13P (624.2910634)

PEth 28:6;O

C33H53O9P (624.3427018)

PM 29:6;O

C33H53O9P (624.3427018)

ST 25:4;O7;GlcA

C31H44O13 (624.2781774)

ST 26:3;O6;GlcA

C32H48O12 (624.3145608)

ST 27:2;O5;GlcA

C33H52O11 (624.3509442)

ST 25:5;O8;Hex

C31H44O13 (624.2781774)

ST 26:4;O7;Hex

C32H48O12 (624.3145608)

(1's,2r,2's,5'r,6'r,10's,12's,14's)-5'-[(2s,3r,5r)-5,6-dihydroxy-5,6-dimethyl-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-6',10'-dimethyl-13'-oxaspiro[oxolane-2,11'-tetracyclo[7.5.0.0²,⁶.0¹²,¹⁴]tetradecan]-8'-en-5-one

C33H52O11 (624.3509442)

methyl (2e,4e,6e,8e,10e,12e,14e,16e,18e,20e)-2,6,11,15,19,23-hexamethyl-23-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracosa-2,4,6,8,10,12,14,16,18,20-decaenoate

C37H52O8 (624.3661992)

(1s,2s,4s,6r,7s,8r,9s,11r,12s,13r,14r,16r)-7,9,13-trimethyl-6-[3-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-ene-6,11,14,16-tetrol

C33H52O11 (624.3509442)

1-(2,3-dihydroxy-6-methyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl)-7,8-dihydroxy-9a,11a-dimethyl-1h,2h,4h,5ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-5-one

C33H52O11 (624.3509442)

(2s,4'as,9'as)-4',6',7-triisopropyl-3',4'a,5',6,7',8-hexamethoxy-3,4,9',9'a-tetrahydrospiro[1-benzopyran-2,1'-xanthen]-2'-one

C36H48O9 (624.3298158)

(2r,3r,4r,5r,6s)-4-{[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-methyl-5-[(3-methylbutanoyl)oxy]oxan-2-yl]oxy}-5-hydroxy-6-(2-hydroxy-6-isopropyl-3-methylphenoxy)-2-methyloxan-3-yl (2z)-2-methylbut-2-enoate

C32H48O12 (624.3145608)

6-(acetyloxy)-7,9-dihydroxy-1,7-dimethyl-8-[(2-methylbut-2-enoyl)oxy]-3-[(2-methylbutanoyl)oxy]-4-(2-methyloxiran-2-yl)-11-oxabicyclo[8.1.0]undecan-2-yl 2-methylbut-2-enoate

C32H48O12 (624.3145608)

(1s,2s,3s,4s,5r,7s,8s,9s,10s)-5-(acetyloxy)-2,4-dihydroxy-4,10-dimethyl-9-{[(2z)-2-methylbut-2-enoyl]oxy}-8-{[(2r)-2-methylbutanoyl]oxy}-7-[(2r)-2-methyloxiran-2-yl]-11-oxabicyclo[8.1.0]undecan-3-yl (2z)-2-methylbut-2-enoate

C32H48O12 (624.3145608)

5-(acetyloxy)-14-(butanoyloxy)-6,10-dihydroxy-3-isopropyl-6,10,14-trimethyl-11-(prop-2-enoyloxy)-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl butanoate

C33H52O11 (624.3509442)

(1r,3r,9r,10r,13r,15r,21s,23r)-23-{[(2r,3r,4r,5r,6s)-4,5-dihydroxy-3-methoxy-6-methyloxan-2-yl]oxy}-13-hydroxy-15-(hydroxymethyl)-3,10-dimethyl-16,25,26-trioxatricyclo[19.3.1.1⁹,¹²]hexacosa-4,6,18-trien-17-one

C33H52O11 (624.3509442)

n-(1-{[(4e,10e,12z)-6,22-dihydroxy-16-methoxy-5,7-dimethyl-18-oxo-25-oxa-19-azatetracyclo[12.9.2.0¹⁵,¹⁹.0²⁰,²⁴]pentacosa-1(24),4,10,12,20,22-hexaen-8-yl]oxy}-1-oxopropan-2-yl)-4-methylpentanimidic acid

C35H48N2O8 (624.3410488)

2-(3,4-dihydroxy-4-methylpentyl)-6,10-dimethyl-12-(2,4,6,9-tetrahydroxy-5,7-dimethyl-1,3-dioxophenalen-2-yl)dodeca-2,6,10-trienoic acid

C35H44O10 (624.2934324)

(1s)-1-{[4-(5-{[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-2-methoxyphenoxy)phenyl]methyl}-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol

C38H44N2O6 (624.3199204)

(2r,3r,4r,5r,6r)-5-hydroxy-6-{[(2e)-7-hydroxy-3,7-dimethylocta-2,5-dien-1-yl]oxy}-2-(hydroxymethyl)-4-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

C31H44O13 (624.2781774)

(1r,14r,30r)-21-hydroxy-9,20,25-trimethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.2³,⁶.1⁸,¹².1¹⁴,¹⁸.0²⁷,³¹.0²²,³³]hexatriaconta-3,5,8(34),9,11,18(33),19,21,24,26,31,35-dodecaen-30-ium-30-olate

C37H40N2O7 (624.283537)

10,11,16,27-tetramethoxy-4-methyl-13,29-dioxa-4,21-diazaheptacyclo[28.2.2.1¹⁴,¹⁸.1²⁴,²⁸.0³,⁸.0⁷,¹².0²²,³⁶]hexatriaconta-1(32),7(12),8,10,14,16,18(36),24,26,28(35),30,33-dodecaen-15-ol

C37H40N2O7 (624.283537)

(2r,3r,4r,5r,6r)-6-{[(2e)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-5-hydroxy-2-(hydroxymethyl)-4-{[(2s,3r,4s,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl (2e)-3-(3,4-dihydroxyphenyl)prop-2-enoate

C31H44O13 (624.2781774)